Croatto, Giovanni http://orcid.org/0000-0003-0591-3936
Vancampfort, Davy
Miola, Alessandro
Olivola, Miriam http://orcid.org/0000-0003-0914-0539
Fiedorowicz, Jess G. http://orcid.org/0000-0003-2057-4071
Firth, Joseph
Alexinschi, Ovidiu
Gaina, Marcel A. http://orcid.org/0000-0003-0533-9014
Makkai, Vladimir
Soares, Fernanda Cunha
Cavaliere, Leandro http://orcid.org/0000-0002-9792-4079
Vianello, Giorgia
Stubbs, Brendon
Fusar-Poli, Paolo http://orcid.org/0000-0003-3582-6788
Carvalho, Andre F. http://orcid.org/0000-0002-2500-5671
Vieta, Eduard http://orcid.org/0000-0002-0548-0053
Cortese, Samuele
Shin, Jae Il http://orcid.org/0000-0003-2326-1820
Correll, Christoph U.
Solmi, Marco
Article History
Received: 29 November 2021
Revised: 17 August 2022
Accepted: 26 August 2022
First Online: 22 September 2022
Competing interests
: Dr. Marco Solmi received honoraria/has been a consultant for Angelini, Lundbeck, Otsuka. Dr. Correll has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Damitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris.. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. Dr. Firth has received honoraria / consultancy fees from Atheneum, ParachuteBH and Nirakara, independent of this work. All other authors have nothing to disclose.
Free to read: This content has been made available to all.